BACKGROUND: Randomized controlled trials testing the association between vitamin D status and upper respiratory tract infection (URTI) have given mixed results. During a multicenter, randomized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D(3) supplementation reduced winter episodes and duration of URTI and its composite syndromes, influenza-like illness (ILI; fever and ≥2 of sore throat, cough, muscle ache, or headache) and colds (no fever, and ≥2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen or tender neck glands). METHODS: The 2259 trial participants were aged 45-75, in good health, had a history of colorectal adenoma, and had a serum 25-hydroxyvitamin D level ≥12 ng/mL. They were randomized to vitamin D(3) (1000 IU/day), calcium (1200 mg/day), both, or placebo. Of these, 759 participants completeddaily symptom diaries. Secondary data included semiannual surveys of all participants. RESULTS: Among those who completed symptom diaries, supplementation did not significantly reduce winter episodes of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI], .79-1.09) including colds (RR, 0.93; 95% CI, .78-1.10) or ILI (RR, 0.95; 95% CI, .62-1.46), nor did it reduce winter days of illness (RR, 1.13; 95% CI, .90-1.43). There was no significant benefit according to adherence, influenza vaccination, body mass index, or baseline vitamin D status. Semiannual surveys of all participants (N = 2228) identified no benefit of supplementation on ILI (odds ratio [OR], 1.14; 95% CI, .84-1.54) or colds (OR, 1.03; 95% CI, .87-1.23). CONCLUSIONS:Supplementation with 1000 IU/day vitamin D(3) did not significantly reduce the incidence or duration of URTI in adults with a baseline serum25-hydroxyvitamin D level ≥12 ng/mL.
RCT Entities:
BACKGROUND: Randomized controlled trials testing the association between vitamin D status and upper respiratory tract infection (URTI) have given mixed results. During a multicenter, randomized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D(3) supplementation reduced winter episodes and duration of URTI and its composite syndromes, influenza-like illness (ILI; fever and ≥2 of sore throat, cough, muscle ache, or headache) and colds (no fever, and ≥2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen or tender neck glands). METHODS: The 2259 trial participants were aged 45-75, in good health, had a history of colorectal adenoma, and had a serum 25-hydroxyvitamin D level ≥12 ng/mL. They were randomized to vitamin D(3) (1000 IU/day), calcium (1200 mg/day), both, or placebo. Of these, 759 participants completed daily symptom diaries. Secondary data included semiannual surveys of all participants. RESULTS: Among those who completed symptom diaries, supplementation did not significantly reduce winter episodes of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI], .79-1.09) including colds (RR, 0.93; 95% CI, .78-1.10) or ILI (RR, 0.95; 95% CI, .62-1.46), nor did it reduce winter days of illness (RR, 1.13; 95% CI, .90-1.43). There was no significant benefit according to adherence, influenza vaccination, body mass index, or baseline vitamin D status. Semiannual surveys of all participants (N = 2228) identified no benefit of supplementation on ILI (odds ratio [OR], 1.14; 95% CI, .84-1.54) or colds (OR, 1.03; 95% CI, .87-1.23). CONCLUSIONS: Supplementation with 1000 IU/day vitamin D(3) did not significantly reduce the incidence or duration of URTI in adults with a baseline serum 25-hydroxyvitamin D level ≥12 ng/mL.
Entities:
Keywords:
randomized controlled trial; upper respiratory tract infection; vitamin D
Authors: Semira Manaseki-Holland; Ghulam Qader; Mohammad Isaq Masher; Jane Bruce; M Zulf Mughal; Daniel Chandramohan; Gijs Walraven Journal: Trop Med Int Health Date: 2010-08-17 Impact factor: 2.622
Authors: Noelle-Angelique M Molinari; Ismael R Ortega-Sanchez; Mark L Messonnier; William W Thompson; Pascale M Wortley; Eric Weintraub; Carolyn B Bridges Journal: Vaccine Date: 2007-04-20 Impact factor: 3.641
Authors: David R Murdoch; Sandy Slow; Stephen T Chambers; Lance C Jennings; Alistair W Stewart; Patricia C Priest; Christopher M Florkowski; John H Livesey; Carlos A Camargo; Robert Scragg Journal: JAMA Date: 2012-10-03 Impact factor: 56.272
Authors: Ilkka Laaksi; Juha-Petri Ruohola; Pentti Tuohimaa; Anssi Auvinen; Riina Haataja; Harri Pihlajamäki; Timo Ylikomi Journal: Am J Clin Nutr Date: 2007-09 Impact factor: 7.045
Authors: James Tamerius; Martha I Nelson; Steven Z Zhou; Cécile Viboud; Mark A Miller; Wladimir J Alonso Journal: Environ Health Perspect Date: 2010-11-19 Impact factor: 9.031
Authors: J G Hansen; W Gao; J Dupuis; G T O'Connor; W Tang; M Kowgier; A Sood; S A Gharib; L J Palmer; M Fornage; S R Heckbert; B M Psaty; S L Booth; Patricia A Cassano Journal: Respir Res Date: 2015-07-01
Authors: Adrian R Martineau; David A Jolliffe; Richard L Hooper; Lauren Greenberg; John F Aloia; Peter Bergman; Gal Dubnov-Raz; Susanna Esposito; Davaasambuu Ganmaa; Adit A Ginde; Emma C Goodall; Cameron C Grant; Christopher J Griffiths; Wim Janssens; Ilkka Laaksi; Semira Manaseki-Holland; David Mauger; David R Murdoch; Rachel Neale; Judy R Rees; Steve Simpson; Iwona Stelmach; Geeta Trilok Kumar; Mitsuyoshi Urashima; Carlos A Camargo Journal: BMJ Date: 2017-02-15
Authors: Alicia K Gerke; Alejandro A Pezzulo; Fan Tang; Joseph E Cavanaugh; Thomas B Bair; Emily Phillips; Linda S Powers; Martha M Monick Journal: Multidiscip Respir Med Date: 2014-03-26
Authors: Emma C Goodall; Andrea C Granados; Kathy Luinstra; Eleanor Pullenayegum; Brenda L Coleman; Mark Loeb; Marek Smieja Journal: BMC Infect Dis Date: 2014-05-19 Impact factor: 3.090